Recursion Pharmaceuticals (RXRX) Assets (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Assets came in at $1.3 billion in Q1 2026, up 2.63% YoY from $1.3 billion in Q1 2025, and down 9.13% on a QoQ basis from $1.5 billion in Q4 2025.
Recursion Pharmaceuticals (RXRX) Assets (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Assets data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Assets rose 2.63% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 2.63% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.76% from the prior year.
- Assets eased to $1.3 billion in Q1 2026, from $1.5 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $1.5 billion in Q4 2025 to a low of $557.8 million in Q1 2024.
- A 5-year average of $919.3 million and a median of $726.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets surged 170.03% — and 2023, when it slipped 14.56%.
- Tracing RXRX's Assets over 5 years: stood at $701.3 million in 2022, then dropped by 6.79% to $653.7 million in 2023, then surged by 121.6% to $1.4 billion in 2024, then advanced by 1.76% to $1.5 billion in 2025, then decreased by 9.13% to $1.3 billion in 2026.
- The last three Assets figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Dec 31, 2025 | 1.47 Bn |
| Sep 30, 2025 | 1.40 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Mar 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 1.45 Bn |
| Sep 30, 2024 | 726.50 Mn |
| Jun 30, 2024 | 775.86 Mn |
| Mar 31, 2024 | 557.85 Mn |
| Dec 31, 2023 | 653.70 Mn |
| Sep 30, 2023 | 630.83 Mn |
| Jun 30, 2023 | 666.70 Mn |
| Mar 31, 2023 | 627.37 Mn |
| Dec 31, 2022 | 701.29 Mn |
| Sep 30, 2022 | 611.53 Mn |
| Jun 30, 2022 | 672.52 Mn |
| Mar 31, 2022 | 734.32 Mn |
| Dec 31, 2021 | 610.35 Mn |
| Sep 30, 2021 | 658.61 Mn |